Form SC 14D9 - Solicitation, recommendation statements:
SEC Accession No. 0001193125-23-186301
Filing Date
2023-07-13
Accepted
2023-07-13 08:18:56
Documents
5

Document Format Files

Seq Description Document Type Size
1 SC 14D9 d533839dsc14d9.htm SC 14D9 531322
2 EX-99.(E)(9) d533839dex99e9.htm EX-99.(E)(9) 9042
3 EX-99.(E)(21) d533839dex99e21.htm EX-99.(E)(21) 67439
4 GRAPHIC g533839g00a55.jpg GRAPHIC 50459
5 GRAPHIC g533839g01a01.jpg GRAPHIC 36323
  Complete submission text file 0001193125-23-186301.txt   724319
Mailing Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 617-336-7540
Sigilon Therapeutics, Inc. (Filed by) CIK: 0001821323 (see all company filings)

EIN.: 474005543 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 14D9
SIC: 2834 Pharmaceutical Preparations

Mailing Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 617-336-7540
Sigilon Therapeutics, Inc. (Subject) CIK: 0001821323 (see all company filings)

EIN.: 474005543 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 14D9 | Act: 34 | File No.: 005-92195 | Film No.: 231085777
SIC: 2834 Pharmaceutical Preparations